Edgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology

Articles by Edgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology

EGFR-Mutated NSCLC: Looking Ahead

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

RELAY Trial Regimen Adverse-Event Overview

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

TKI Plus Antiangiogenic Combination Therapy

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

TKI Combination Clinical Trials: Practical Implications in US and UK

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

EGFR TKI Plus Chemotherapy Combination Strategy

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

Data Updates From the GioTag Study

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

The Use of TKIs in Patients With Brain Metastases

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

Approved Frontline TKIs for EGFR-Mutated Disease

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

Molecular Testing Prior to Metastases

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

Metastatic NSCLC: The Role of Liquid Biopsy

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

Molecular Testing in Metastatic NSCLC

ByEdgardo S. Santos Castillero, MD, FACP, Florida Precision Oncology,John V. Heymach, MD, PhD, MD Anderson Cancer Center

September 29th 2020

Latest Updated Articles

Metastatic NSCLC: The Role of Liquid Biopsy
September 29th 2020
EGFR TKI Plus Chemotherapy Combination Strategy
September 29th 2020
TKI Combination Clinical Trials: Practical Implications in US and UK
September 29th 2020
EGFR-Mutated NSCLC: Looking Ahead
September 29th 2020
Approved Frontline TKIs for EGFR-Mutated Disease
September 29th 2020
Molecular Testing in Metastatic NSCLC
September 29th 2020

Trending on OncLive

FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer

FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC

Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC

FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC

Etentamig, Iberdomide, and Long-Term PERSEUS Data Headline Key Myeloma Findings From IMS 2026